AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP

Who can take part

• Volunteer to participate, understand and sign an informed consent form
• Age ≥ 18 years old, regardless of gender
• Patient diagnosed with coronary heart disease requiring percutaneous coronary intervention
• Complete all planned percutaneous coronary intervention during hospitalization
• Patient must be treated according to national guidelines for standard treatment of coronary heart disease

Who cannot take part

• Use of colchicine, eplerenone, leflunomide, or artesunate within 30 days before screening
• Current treatment with potent CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, etc
• Current or planned use of medications outside the study protocol that may affect immune or inflammatory responses, including nonsteroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids, immunomodulatory agents, chemotherapeutic agents, etc
• Known hypersensitivity or allergy to colchicine, eplerenone, leflunomide, or artesunate
• Uncontrolled infectious diseases
• Known immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor, etc
• Hepatic dysfunction, defined as alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal (ULN)
• Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m²
• Hyperkalemia, defined as a serum potassium level greater than 5.0 mmol/L
• Thrombocytopenia, defined as a platelet count of less than 100 × 10⁹/L
• Leukopenia, defined as a white blood cell count of less than 3.0 × 10⁹/L
• Anemia, defined as a hemoglobin level of less than 90 g/L
• Requirement for potassium supplementation or potassium-sparing diuretics, including amiloride, spironolactone, triamterene, etc
• Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives
• Any other circumstances in which the investigator judges that the patient is not suitable to participate in the study